Holen Sie sich die Stockscreener-App
34.30
2.68%
0.8895
Schlusskurs vom Vortag:
$33.41
Offen:
$34.32
24-Stunden-Volumen:
263.46K
Relative Volume:
1.00
Marktkapitalisierung:
$984.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.95M
KGV:
-23.09
EPS:
-1.4857
Netto-Cashflow:
$-50.43M
1W Leistung:
+5.70%
1M Leistung:
+20.24%
6M Leistung:
+63.44%
1J Leistung:
+0.00%
1-Tages-Spanne:
$33.17
$34.88
1-Wochen-Bereich:
$31.60
$34.88
52-Wochen-Spanne:
$13.36
$34.88
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
34.33 | 958.66M | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
LBRX Initiated Coverage by Wolfe Research -- Rating Set to Outpe - GuruFocus
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com - Investing.com India
LB Pharmaceuticals Inc (LBRX) Gains 4.83% as Stock Approaches Resistance at $35.10Early Entry Signals - dars.gov.et
LBRXLB Pharmaceuticals Inc Dividends - Finviz
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential - Yahoo Finance
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com - Investing.com South Africa
LB Pharmaceuticals names Christopher Zergebel as SVP - Investing.com
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations - GlobeNewswire
Total assets of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
LB Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LBRX) - TradingView
LBRX Forecast — Price Target — Prediction for 2027 - TradingView
LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright - Investing.com
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Institutional Confidence - TradingKey
LB Pharmaceuticals Inc (LBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LB Pharmaceuticals Inc (LBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LB Pharmaceuticals Inc (LBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LB Pharmaceuticals Inc (LBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LB Pharmaceuticals Inc (LBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LB Pharmaceuticals Inc (LBRX) Edges Lower Amidst Tight Trading RangeVolatility Stop - newsline.com
LBRX Q1 2026 Earnings: Narrower Loss Surpasses Estimates as Pre-Revenue Biotech Tightens SpendingFinal Results - newsline.com
LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition - Stock Titan
LB Pharmaceuticals Inc Announces Resignation of Anna Eramo as Chief Medical Officer, Effective June 15, 2026 - marketscreener.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
[144] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals Stockholders Approve Directors and Auditor - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) elects board and ratifies auditor in 2026 - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) investors back board slate and ratify BDO as 2026 auditor - Stock Titan
LBRX Options Volatility — NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc (LBRX) Shows Modest Uptick as Stock Holds Above Key SupportPut Spread Alert - newsline.com
LBRX Q1 2026 Earnings: EPS Beat Estimates as Biotech Advances PipelineEarnings Quality Score - newsline.com
LB Pharmaceuticals (LBRX) Slips 1.28% as Stock Holds Above Key Support — What's Next?Reversal Trade - newsline.com
LB Pharmaceuticals (LBRX) grants director 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) awards 10,000 options to director vesting in 2027 - Stock Titan
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals (LBRX) director receives 12,500 stock options at $27.95 strike - Stock Titan
LB Pharmaceuticals (LBRX) director receives 10,000 stock options at $27.95 strike - Stock Titan
Director at LB Pharmaceuticals (LBRX) receives grant of 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) director awarded 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) AGM 2026 Summary - Quartr
LBRX: All proposals passed, electing directors and ratifying the auditor for 2026 - TradingView
LB Pharmaceuticals Inc (LBRX) Q1 2026 Earnings: EPS Surprise on Lower-Than-Expected LossOperating Income Trends - newsline.com
LB Pharmaceuticals (LBRX) Q1 2026 Earnings: EPS Surprise Signals Improving Operational DisciplineBook Value Growth - newsline.com
LBRX News Today | Why did LB Pharmaceuticals stock go up today? - MarketBeat
Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks - Stock Titan
LBRX Options Chain — NASDAQ:LBRX - TradingView
Top LB Pharmaceuticals (LBRX) Competitors 2026 - MarketBeat
Bipolar Depression Market Poised for Robust Growth with Upcoming Novel Therapies and Improved Diagnostics - Barchart.com
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lb Pharmaceuticals Inc-Aktie (LBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
2,000,000 |
30,000,000 |
2,686,138 |
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):